Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 10;11:181. doi: 10.1038/s41467-019-13914-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a Immunoprecipitation (IP) and Western blot analysis showing that OGT overexpression enhances PLIN1 O-GlcNAcylation and the catalytic dead mutation of OGT greatly impairs its ability to catalyze PLIN1 O-GlcNAcylation; RL2 is an antibody against O-GlcNAc moieties. b Overlapping of predicted O-GlcNAcylation sites determined by three independent analyses. c Final candidate sites, known PKA phosphorylation sites (red colored) were included, common sites from b that are adjacent to the PKA sites (green colored) were also included. d, e IP, Western blot analysis, and quantification results showing that OGT catalyzes PLIN1 O-GlcNAcylation primarily at serine 492 and serine 517 (n = 10 for WT positive control, 4–5 for other groups). f, g IP, Western blot analysis, and quantification results showing that serine 492 to alanine and serine 517 to alanine double mutation in PLIN1 (PLIN1-AA) largely eliminated its overall O-GlcNAcylation (n = 8 for WT positive control, 3–8 for other groups); data are presented as mean ± s.e.m. Statistical analysis: ANOVA with Dunnett’s multiple comparisons, *p < 0.05, **p < 0.01, and ***p < 0.001. Source data are provided as a Source Data file.